Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 5.90
-0.09 (-1.50%)
At close: Mar 9, 2026
Xbrane Biopharma AB Revenue
In the year 2025, Xbrane Biopharma AB had annual revenue of 152.35M SEK, down -23.33%. Xbrane Biopharma AB had revenue of 9.09M in the quarter ending December 31, 2025, a decrease of -86.19%.
Revenue
152.35M
Revenue Growth
-23.33%
P/S Ratio
0.80
Revenue / Employee
5.25M
Employees
26
Market Cap
121.55M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 152.35M | -46.37M | -23.33% |
| Dec 31, 2024 | 198.72M | -40.01M | -16.76% |
| Dec 31, 2023 | 238.73M | 181.11M | 314.33% |
| Dec 31, 2022 | 57.62M | 46.91M | 438.03% |
| Dec 31, 2021 | 10.71M | - | - |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRLAB Therapeutics AB | 57.46M |
| Alligator Bioscience AB | 4.42M |
| NextCell Pharma AB | 9.83M |
| Simris Group AB (PUBL) | 1.62M |
| Magle Chemoswed Holding AB | 300.49M |
| Biosergen AB | 2.09M |
| OncoZenge AB | 2.78M |
| Scandinavian ChemoTech AB | 12.29M |